Roche: positive results for prasinezumab in Parkinson's disease

(CercleFinance.com) - Roche presents results from a Phase IIb study of prasinezumab in 586 patients with early-stage Parkinson's disease.


The treatment showed potential clinical efficacy on the primary endpoint (confirmed motor progression) with an HR=0.84, but without reaching statistical significance (p=0.0657). A pre-specified analysis revealed a stronger effect in patients on levodopa (HR=0.79). Positive trends were also observed on several secondary and exploratory endpoints.

Prasinezumab is well tolerated, with no new safety signals.

Roche is continuing open-label Phase II and IIb studies to evaluate the observed effects, and will collaborate with health authorities to determine next steps.

Full results will be presented at a forthcoming medical conference.


Copyright (c) 2024 CercleFinance.com. All rights reserved.